Spark Therapeutics Inc. (NASDAQ:ONCE) shares fell 5.4% on Tuesday . The stock traded as low as $55.52 and last traded at $55.72, with a volume of 161,854 shares. The stock had previously closed at $58.87.

Several research firms have recently weighed in on ONCE. Jefferies Group restated a “hold” rating on shares of Spark Therapeutics in a research note on Sunday, June 12th. Zacks Investment Research lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 26th. Cowen and Company reiterated a “buy” rating and issued a $75.00 price target on shares of Spark Therapeutics in a research note on Thursday, May 19th. Wedbush reiterated an “underperform” rating and issued a $21.00 price target on shares of Spark Therapeutics in a research note on Thursday, May 19th. Finally, Evercore ISI assumed coverage on shares of Spark Therapeutics in a research note on Tuesday, April 12th. They issued a “buy” rating and a $37.00 price target on the stock. Three research analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. Spark Therapeutics has a consensus rating of “Hold” and an average target price of $58.70.

The stock has a 50-day moving average price of $52.41 and a 200 day moving average price of $40.51. The firm’s market cap is $1.60 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, May 4th. The company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.11. The firm had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $1.48 million. The company’s revenue was down 43.2% on a year-over-year basis. Equities research analysts expect that Spark Therapeutics Inc. will post ($3.81) earnings per share for the current year.

In other news, Director Anand Mehra sold 500 shares of the stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $60.00, for a total value of $30,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey D. Marrazzo sold 25,000 shares of the stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $46.01, for a total transaction of $1,150,250.00. Following the completion of the transaction, the chief executive officer now owns 255,000 shares in the company, valued at approximately $11,732,550. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Spark Therapeutics stock. RS Investment Management Co. LLC raised its stake in Spark Therapeutics Inc. (NASDAQ:ONCE) by 2.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 452,349 shares of the company’s stock after buying an additional 9,957 shares during the period. RS Investment Management Co. LLC owned approximately 1.83% of Spark Therapeutics worth $20,496,000 at the end of the most recent quarter.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.